EFFECT OF BOSENTAN TREATMENT: CASE STUDY AMONG PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE IN QUEEN SIRIKIT HEART CENTER OF THE NORTHEAST
Keywords:
effect, bosentan treatment, congenital heart disease, pulmonary arterial hypertensionAbstract
The objective of this preliminary study was to evaluate the effects of Bosentan administration in patients with congenital heart disease with hypertension of the pulmonary artery between May 2015 - June 2020. This study found 33 subjects according to the specified criteria were mostly female, mean age 23 ± 0.8 years. The male sex ratio was high. There had no associated disease. It was found that after receiving Bosentan, mean PAP by RHC, PVR by RHC and NT-pro BNP reduced statistically (p<.001; mean: 9.4, 1.64, 642; 95% CI 7:12.5, 1.09:2.36, 313.8: 809.15) Respectively. In addition, the cardiac index (CI), mean RV TAPSE by echo and 6MWD in creased statistically significance (p<0.001; mean = 0.99, 5.64, 66.39; 95%CI 0.66: 1.37, 4.75:6.54, 56.08:76.71), respectively. This study demonstrated that Bosentan significantly improved the therapeutic effect of both exercise performance and clinical efficacy. Improved right ventricular function, decreased in pulmonary arterial pressure and pulmonary vascular resistance.
Downloads
References
Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European heart journal 2009; 30(20): 2493-2537.
Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, et al. Eisenmenger syndrome.Factors relating to deterioration and death. European heart journal 1998; 19(12): 1845-1855.
Hw F. Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
Duffels MG, Engelfriet PM, Berger RM, van Loon RL, Hoendermis E, Vriend JW, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. International journal of cardiology 2007; 120(2): 198-204.
Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan Randomized Trial of Endothelin Antagonist Therapy -5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114(1): 48-54.
Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. The Journal of heart and lung transplantation 2007; 26(2): 181-187.
Peacock A, Naeije R, Galie N, Reeves JT. End points in pulmonary arterial hypertension: the way forward. European Respiratory Journal 2004; 23(6): 947-953.
Duffels MG, Vis JC, van Loon RL, Nieuwkerk PT, van Dijk AP, Hoendermis ES, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome. The American journal of cardiology 2009; 103(9): 1309-1315.
Schuuring MJ, Vis JC, Duffels MC, Bouma BJ, Mulder BJ. Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Therapeutics and clinical risk management 2010; 6: 59-65.
Van Loon RL, Hoendermis ES, Duffels MG, Vonk-Noordegraaf A, Mulder BJ, Hillege HL, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic – to -pulmonary shunt: does the beneficial effect persist?. American heart journal 2007; 154(4): 776-782.
Gatzoulis MA, Beghetti M, Galie N, Granton J, Berger RM, Lauer A, et al. Longer - term bosentan therapy improves functional capacity in Eisenmenger syndrome: result of the BREATHE-5 open-label extension study. Int J Cardiol 2008; 127: 27-32.
Berger RM, Beghetti M, Galiè N, Gatzoulis MA, Granton J, Lauer A, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo - controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. International journal of cardiology 2010; 144(3): 373-378.
Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 2007; 93(3): 350-354.
Vis JC, Duffels MG, Mulder P, de Bruin-Bon RH, Bouma BJ, Berger RM, et al. Prolonged beneficial effect of bosentan treatment and 4 -year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. International journal of cardiology 2013; 164(1): 64-69.
Diller GP, Alonso - Gonzalez R, Dimopoulos K, Alvarez - Barredo M, Koo C, Kempny A, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. International journal of cardiology. 2013; 167(3): 840-847.
Diller GP, Dimopoulos K, Kaya MG, Harries C, Uebing A, Li W et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 2007; 93(8): 974-976.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the x may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.use or modification of the articles is prohibited without permission.
statements expressed in the articles are solely the opinions of the authors.
authors are fully responsible for the content and accuracy of their articles.
other reuse or republication requires permission from the journal."
